{"groups":[{"description":"Patients receive adavosertib 300 mg PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Adavosertib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"19"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"comment":"Primary efficacy analysis set","type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients were assigned to this NCI-MATCH subprotocol (EAY131-Z1I) using a prospectively defined NCI-designed informatics rules algorithm (MATCHBOX). Adult patients with solid tumors carrying BRCA1/2 PVs were eligible if they had progressed on standard treatment or had no standard treatment available.","recruitmentDetails":"Subprotocol Z1I was activated on March 13, 2017. Thirty-three patients were enrolled on EAY131-Z1I between March 24, 2017, and August 9, 2017."}